A retrospective study assessing the Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation in real-world setting
Latest Information Update: 11 Aug 2021
At a glance
- Drugs Letermovir (Primary)
- Indications Cytomegalovirus infections
- Focus Therapeutic Use
- 11 Aug 2021 Primary endpoint met (Cumulative incidence of CS-CMVi (CMV reactivation demanding PET, and/or CMV disease) at day +100 post alloHCT) according to the results published in the Annals of Hematology
- 11 Aug 2021 New trial record
- 01 Aug 2021 Results published in the Annals of Hematology